mRNA production partnership to scale-up COVID-19 vaccine development
GreenLight Biosciences and Samsung Biologics announce mRNA production partnership to scale mRNA vaccine production to a commercial level with Samsung's expanded mRNA drug substance manufacturing site.
Biotech company GreenLight Biosciences based in Boston, USA have announced the first successful completion of a commercial-scale engineering run for their mRNA production partnership with Samsung Biologics, a leading CDMO based in Incheon, South Korea.
The strategic partnership was announced in late 2021, with the goal of transferring technology and scaling-up from a lab bench to commercial facilities provided by Samsung. The process from drug substance and lipid nanoparticle formulation straight through to bulk drug product can now be completed in the same facility. With Samsung’s RNA platform, GreenLight can now progress from conceptualizing an mRNA vaccine to delivering material for clinical trials in less than 2 years, allowing them to supply an mRNA vaccine at a commercial scale.
In early 2022, Samsung Biologics completed the expansion of their mRNA drug substance manufacturing suite at the Songdo headquarters, providing a fully equipped facility for end-to-end mRNA production for their clients.
CEO and President of Samsung Biologics John Rim commented: “This demonstrates a major achievement in our continuing goal to offer one-stop end-to-end mRNA production from drug substance to aseptic fill finish to commercial release, all from a single site as we strive across our biomanufacturing network to fight the pandemic.”
GreenLight CEO Andrey Zarur added: “One of the greatest challenges when producing quality pharmaceuticals is advancing from a small lab to large-scale commercial production… We are grateful for the help and support of Samsung in demonstrating that our small mRNA process can scale in a linear fashion to the industrial scale that will be needed to help satisfy the vaccine needs of humanity.”
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance